natgillin/translations-raw huggingface dataset:
All patients were also taking metformin. 
Vsi bolniki so prejemali tudi metformin.
Nausea occurs mainly at the start of treatment and decreases over time. 
Slabost se pojavi zlasti na začetku zdravljenja in se sčasoma zmanjša.
They should be given appropriate training and should follow the user instructions. 
Za to morajo biti ustrezno usposobljeni in slediti navodilom za uporabo.
The European Commission granted a marketing authorisation valid throughout the European Union for Bydureon on 17 June 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Bydureon, veljavno po vsej Evropski uniji, izdala 17. junija 2011.
The full EPAR for Bydureon can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Bydureon je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This is a summary of the European public assessment report (EPAR) for Bydureon. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Bydureon.
What measures are being taken to ensure the safe and effective use of Bydureon? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Bydureon?
This means that it acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin released by the pancreas in response to food. 
To pomeni, da deluje enako kot inkretini (hormoni, proizvedeni v črevesu), in sicer s povečevanjem količine insulina, ki ga sprošča trebušna slinavka ob odzivu na hrano.
The Agency therefore decided that Bydureon's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Agencija je tako sklenila, da so koristi zdravila Bydureon večje od z njim povezanih tveganj, in priporočila, da se zanj izda dovoljenje za promet.
Patients inject themselves using a kit supplied with the medicine. 
Bolniki si zdravilo injicirajo sami z uporabo kompleta, ki je priložen zdravilu.
In all of the studies, the main measure of effectiveness was the reduction in the amount of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled. 
V vseh študijah je bilo glavno merilo učinkovitosti zmanjšanje količine snovi v krvi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je glukoza v krvi nadzorovana.
The European Medicines Agency noted that the benefits of Bydureon, such as its effect on reducing the levels of HbA1c, compare well with those of comparator medicines and that its side effects are manageable. 
Evropska agencija za zdravila je poudarila, da so koristi zdravljenja z zdravilom Bydureon, npr. učinek na zmanjševanje ravni HbA1c, dobro primerljive s primerjalnimi zdravili in da so njegovi neželeni učinki obvladljivi.
Bydureon was effective at controlling blood glucose in six main studies involving nearly 2700 patients with type 2 diabetes. 
Zdravilo Bydureon je bilo za nadzorovanje glukoze v krvi učinkovito v šestih glavnih študijah, v katere je bilo vključenih skoraj 2 700 bolnikov s sladkorno boleznijo tipa 2.
When adding Bydureon to a sulphonylurea, the doctor may need to reduce the dose of the sulphonylurea because there is a risk of hypoglycaemia (low blood sugar levels). 
Kadar se zdravilo Bydureon dodaja sulfonilsečnini, mora zdravnik morda zmanjšati odmerek sulfonilsečnine, saj obstaja tveganje za pojav hipoglikemije (nizke ravni sladkorja v krvi).
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bydureon have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Bydureon upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Bydureon is given by injection under the skin once a week on the same day each week in the abdomen (belly), thigh or back of the upper arm. 
Zdravilo Bydureon se daje z injekcijo pod kožo enkrat tedensko, na isti dan v tednu, v trebuh, stegno ali zadnji del nadlakti.
This helps to control blood glucose levels. 
To pomaga pri nadzorovanju ravni glukoze v krvi.
Patients using both Bydureon and insulin should inject the medicines separately. 
Bolniki, ki hkrati uporabljajo zdravilo Bydureon in insulin, si morajo zdravili vbrizgati ločeno.
Prolonged-release means that the active substance is released slowly after being injected. 
Podaljšano sproščanje pomeni, da se zdravilna učinkovina po injiciranju počasi sprošča.
This leads to excess glucose in the blood. 
To vodi do presežka glukoze v krvi.
Other information about Bydureon 
Druge informacije o zdravilu Bydureon
What is Bydureon and what is it used for? 
Kaj je zdravilo Bydureon in za kaj se uporablja?
Most side effects are mild to moderate in intensity. 
Neželeni učinki so bili večinoma blagi do zmerni.
Bydureon is available as a powder and solvent that are mixed together to make a prolonged-release suspension for injection providing 2 mg of exenatide. 
Zdravilo Bydureon je na voljo v obliki praška in vehikla, ki se zmešata za pripravo suspenzije za injiciranje s podaljšanim sproščanjem, ki vsebuje 2 mg eksenatida.
For more information about treatment with Bydureon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Bydureon preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
In addition, reactions at the site of injection (itching and redness), low blood sugar levels (when used with a sulphonylurea) and headache occur. 
Pojavile so se tudi reakcije na mestu injiciranja (srbečica in pordelost), nizke ravni sladkorja v krvi (pri uporabi s sulfonilsečnino) in glavoboli.
For practical information about using Bydureon, patients should read the package leaflet or contact their doctor or pharmacist. 
Za praktične informacije o uporabi zdravila Bydureon naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Adding Bydureon to metformin or pioglitazone does not cause hypoglycaemia. 
Če se zdravilo Bydureon dodaja metforminu ali pioglitazonu, se hipoglikemija ne pojavi.
What benefits of Bydureon have been shown in studies? 
Kakšne koristi je zdravilo Bydureon izkazalo v študijah?
What are the risks associated with Bydureon? 
Kakšna tveganja so povezana z zdravilom Bydureon?
Bydureon is a diabetes medicine used together with other diabetes medicines including long-acting insulin to treat adults with type 2 diabetes whose blood glucose (sugar) levels are not adequately controlled with the other medicines. 
Zdravilo Bydureon je zdravilo za zdravljenje sladkorne bolezni, ki se skupaj z drugimi zdravili za zdravljenje sladkorne bolezni, vključno z dolgodelujočim insulinom, uporablja za zdravljenje odraslih bolnikov s sladkorno boleznijo tipa 2, pri kateri ravni glukoze (sladkorja) v krvi niso zadostno nadzorovane z drugimi zdravili.
Why is Bydureon approved? 
Zakaj je bilo zdravilo Bydureon odobreno?
For the full list of side effects and restrictions with Bydureon, see the package leaflet. 
Za celoten seznam neželenih učinkov in omejitev pri uporabi zdravila Bydureon glejte navodilo za uporabo.
The most common side effects with Bydureon are nausea (feeling sick) and diarrhoea. 
Najpogostejša neželena učinka zdravila Bydureon sta slabost (siljenje na bruhanje) in driska.
It is not intended to provide practical advice on how to use Bydureon. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
The first two studies (in a total of 555 patients) compared Bydureon with another medicine also containing exenatide but given twice daily, both given as add-on treatment to oral diabetes medicines or diet and exercise alone. 
V prvih dveh študijah (pri skupno 555 bolnikih) so zdravilo Bydureon primerjali z drugim zdravilom, ki tudi vsebuje eksenatid, a se daje dvakrat dnevno; obe zdravili se dajeta kot dodatek k peroralnim zdravilom za zdravljenje sladkorne bolezni ali v kombinaciji z dieto in telesno vadbo samo.
The active substance in Bydureon, exenatide, is an ‘incretin mimetic'. 
Zdravilna učinkovina v zdravilu Bydureon, eksenatid, je „mimetik inkretina“.
Bydureon contains the active substance exenatide. 
Zdravilo Bydureon vsebuje zdravilno učinkovino eksenatid.
The third study (in 514 patients) compared Bydureon with sitagliptin or pioglitazone as add-on treatment to metformin. 
V tretji študiji (pri 514 bolnikih) so zdravilo Bydureon primerjali s sitagliptinom ali pioglitazonom kot dodatnim zdravilom pri zdravljenju z metforminom.
In the sixth study (in 464 patients), Bydureon given together with insulin glargine with or without metformin was compared with placebo (dummy treatment) also given with insulin glargine with or without metformin. 
V šesti študiji (pri 464 bolnikih) so zdravilo Bydureon v kombinaciji z insulinom glarginom skupaj z metforminom ali brez njega primerjali s placebom (zdravilom brez zdravilne učinkovine), ki so ga prav tako dajali v kombinaciji z insulinom glarginom skupaj z metforminom ali brez njega.
How does Bydureon work? 
Kako zdravilo Bydureon deluje?
How is Bydureon used? 
Kako se zdravilo Bydureon uporablja?
In the fifth study (in 695 patients), Bydureon given with dapagliflozin was compared with Bydureon alone and dapagliflozin alone. 
V peti študiji (pri 695 bolnikih) so zdravljenje s kombinacijo zdravila Bydureon in dapagliflozina primerjali z zdravljenjem samo z zdravilom Bydureon ali dapagliflozinom kot samostojnima zdraviloma.
In the first study, Bydureon reduced HbA1c levels by an average of 1.9 percentage points after 30 weeks of treatment, compared with an average reduction of 1.5 points with exenatide given twice daily. 
V prvi študiji je zdravilo Bydureon znižalo ravni HbA1c v povprečju za 1,9 odstotne točke po 30 tednih zdravljenja v primerjavi s povprečnim znižanjem za 1,5 odstotne točke pri jemanju eksenatida dvakrat na dan.
In the second study, the average reduction was 1.6 points after 24 weeks of treatment with Bydureon, compared with an average reduction of 0.9 points with exenatide given twice daily. 
V drugi študiji je bilo povprečno znižanje ravni HbA1c po 24 tednih zdravljenja z zdravilom Bydureon 1,6 točke v primerjavi s povprečnim znižanjem za 0,9 točke pri jemanju eksenatida dvakrat na dan.
The average reduction with Bydureon plus dapagliflozin was 2.0 points after 28 weeks, compared with an average reduction of 1.6 points with Bydureon alone and 1.4 points with dapagliflozin alone. 
Povprečno znižanje pri zdravljenju s kombinacijo zdravila Bydureon in dapagliflozina je bilo po 28 tednih za 2,0 točke v primerjavi s povprečnim znižanjem za 1,6 točke pri zdravljenju z zdravilom Bydureon oziroma 1,4 točke pri zdravljenju z dapagliflozinom kot samostojnima zdraviloma.
Bydureon reduced HbA1c levels by an average of 1.4 points after 26 weeks of treatment, compared with an average reduction of 0.8 and 1.1 points with sitagliptin and pioglitazone respectively. 
Zdravilo Bydureon je ravni HbA1c po 26 tednih zdravljenja v povprečju znižalo za 1,4 točke v primerjavi s povprečnim znižanjem za 0,8 točke pri zdravljenju s sitagliptinom in 1,1 točke pri zdravljenju s pioglitazonom.
At the start of the study, the patients' HbA1c levels were around 9.3%. 
Na začetku študije je bila raven HbA1c pri bolnikih okoli 9,3 %.
The fourth study (in 456 patients) compared Bydureon with insulin glargine (a long-acting insulin) as add-on treatment to metformin with or without a sulphonylurea. 
V četrti študiji (pri 456 bolnikih) so zdravilo Bydureon kot dodatno zdravilo pri zdravljenju z metforminom s sulfonilsečnino ali brez nje primerjali z insulinom glarginom (dolgodelujočim insulinom).
The average reduction with Bydureon was 1.0 point after 28 weeks, compared with an average reduction of 0.2 points with placebo. 
Po 28 tednih zdravljenja z zdravilom Bydureon se je raven HbA1c v povprečju znižala za 1,0 točke v primerjavi s povprečnim znižanjem za 0,2 točke pri zdravljenju s placebom.
The average reduction with Bydureon was 1.5 points after 26 weeks, compared with an average reduction of 1.3 points with insulin glargine. 
Po 26 tednih zdravljenja z zdravilom Bydureon se je raven HbA1c v povprečju znižala za 1,5 točke v primerjavi s povprečnim znižanjem za 1,3 točke pri zdravljenju z insulinom glarginom.
At the start of the studies, the patients' HbA1c levels were around 8.4%. 
Na začetku študij je bila raven HbA1c pri bolnikih okoli 8,4 %.
At the start of the study, the patients' HbA1c levels were around 8.5%. 
Na začetku študije je bila raven HbA1c pri bolnikih okoli 8,5 %.
At the start of the study, the patients' HbA1c levels were around 8.3%. 
Na začetku študije je bila raven HbA1c pri bolnikih okoli 8,3 %.
The most important serious side effects are serious infections. 
Najpomembnejši resni neželeni učinki so resne okužbe.
However, these side effects are considered manageable. 
Vendar se ti neželeni učinki štejejo za obvladljive.
Further information on Rinvoq can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/rinvoq. 
Nadaljnje informacije o zdravilu Rinvoq so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/rinvoq.
It is available as 15 mg tablets. 
Zdravilo je na voljo v obliki 15-miligramskih tablet.
This means that it reduces the activity of the immune system. 
To pomeni, da zavira delovanje imunskega sistema.
It must also not be used in patients with severe liver problems or during pregnancy. 
Prav tako se ne sme uporabljati pri bolnikih z resnimi težavami z jetri ali med nosečnostjo.
Studies found that it reduced disease activity when used alone or combined with other medicines. 
Študije so pokazale, da zdravilo zmanjša aktivnost bolezni, če se uporablja samostojno ali v kombinaciji z drugimi zdravili.
The European Medicines Agency therefore decided that Rinvoq's benefits are greater than its risks and that it can be authorised for use in the EU. 
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Rinvoq večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
These studies involved rating disease activity in 28 joints in the body on a standard scale. 
V teh študijah se je s standardno lestvico ocenjevalo aktivnost bolezni v 28 sklepih v telesu.
The recommended dose of Rinvoq is one tablet once a day. 
Priporočeni odmerek zdravila Rinvoq je ena tableta enkrat na dan.
What measures are being taken to ensure the safe and effective use of Rinvoq? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Rinvoq?
Treatment with the medicine should be started and supervised by a doctor experienced in diagnosing and treating rheumatoid arthritis. 
Zdravljenje z zdravilom mora uvesti in nadzorovati zdravnik, ki ima izkušnje z diagnosticiranjem in zdravljenjem revmatoidnega artritisa.
The doctor may interrupt treatment in case of certain side effects, including falls in blood cell counts. 
Zdravnik lahko zdravljenje prekine v primeru nekaterih neželenih učinkov, vključno z zmanjšanjem števila krvnih celic.
Upadacitinib works by blocking the action of enzymes called Janus kinases. 
Upadacitinib deluje tako, da zmanjša delovanje encimov, imenovanih Janusove kinaze.
The patients were being treated with conventional disease-modifying anti-rheumatic medicines (chloroquine, hydroxychloroquine, leflunomide or sulfasalazine, often combined with methotrexate). 
Bolniki so bili zdravljeni z običajnimi imunomodulirajočimi antirevmatiki (klorokvinom, hidroksiklorokvinom, leflunomidom ali sulfasalazinom, pogosto v kombinaciji z metotreksatom).
As for all medicines, data on the use of Rinvoq are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Rinvoq stalno spremljajo.
For more information about using Rinvoq, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Rinvoq glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
The most common side effects with Rinvoq (which may affect more than 1 in 10 people) are upper respiratory tract infections (nose and throat infections). 
Najpogostejši neželeni učinki zdravila Rinvoq (ki se lahko pojavijo pri več kot 1 bolniku od 10) so okužbe zgornjih dihalnih poti (okužbe nosu in žrela).
Other information about Rinvoq 
Druge informacije o zdravilu Rinvoq
Side effects reported with Rinvoq are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Rinvoq, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rinvoq have also been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Rinvoq upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
An overview of Rinvoq and why it is authorised in the EU 
Pregled zdravila Rinvoq in zakaj je odobreno v EU
Rinvoq must not be used in patients with tuberculosis or serious infections. 
Zdravilo Rinvoq se ne sme uporabljati pri bolnikih s tuberkulozo ali resnimi vnetji.
What benefits of Rinvoq have been shown in studies? 
Kakšne koristi zdravila Rinvoq so se pokazale v študijah?
These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control. 
Ti encimi so vključeni v nastajanje procesov, ki povzročajo vnetje, z zaviranjem njihovega učinka pa omogoča nadzor nad vnetjem sklepov.
In patients with rheumatoid arthritis, the immune system (the body's defences) attacks healthy tissue, causing inflammation in the joints. 
Pri bolnikih z revmatoidnim artritisom imunski sistem (obrambni mehanizem telesa) napade zdravo tkivo in povzroči vnetje v sklepih.
Why is Rinvoq authorised in the EU? 
Zakaj je bilo zdravilo Rinvoq odobreno v EU?
Five studies involving a total of nearly 4,400 patients found Rinvoq effective in reducing symptoms in patients with moderate to severe rheumatoid arthritis. 
V petih študijah, v katerih je sodelovalo skupaj skoraj 4 400 bolnikov, je bilo ugotovljeno, da zdravilo Rinvoq učinkovito zmanjšuje simptome pri bolnikih z zmernim do hudim revmatoidnim artritisom.
The company that markets Rinvoq will provide information to healthcare professionals about the risks of infection, harm to the unborn baby if Rinvoq is taken during pregnancy, and problems affecting the heart and circulation. 
Podjetje, ki trži zdravilo Rinvoq, bo zdravstvenim delavcem zagotovilo informacije o tveganjih okužbe, škodljivosti za nerojenega otroka, če se zdravilo Rinvoq jemlje med nosečnostjo, in težavah, ki vplivajo na srce in krvni obtok.
The company will also supply a patient alert card describing warning signs of Rinvoq's serious side effects and how to get help, and a reminder not to use it during pregnancy. 
Pripravilo bo tudi opozorilno kartico za bolnike, na kateri bodo opisani opozorilni znaki resnih neželenih učinkov zdravila Rinvoq in navodila, kako naj bolniki poiščejo pomoč, ter opozorilo, da se zdravilo ne sme uporabljati med nosečnostjo.
Patients treated with Rinvoq may have side effects that include infection, neutropenia (low count of a type of white blood cell), and blood tests that suggest liver or muscle damage and raised blood lipids. 
Pri bolnikih, ki se zdravijo z zdravilom Rinvoq, se lahko pojavijo neželeni učinki, ki vključujejo okužbo, nevtropenijo (nizko število vrste belih krvnih celic), krvne preiskave pa kažejo na okvaro jeter ali poškodbe mišic in povečano raven krvnih lipidov.
It can be used on its own or with methotrexate, another medicine for rheumatoid arthritis. 
Zdravilo se lahko uporablja samostojno ali v kombinaciji z metotreksatom, tj. drugim zdravilom za zdravljenje revmatoidnega artritisa.
Rinvoq is used for moderate or severe rheumatoid arthritis that cannot be controlled well enough with disease-modifying anti-rheumatic medicines or if the patient cannot take these medicines. 
Zdravilo Rinvoq se uporablja pri zmernem ali hudem revmatoidnem artritisu, ki ga ni mogoče dovolj dobro nadzorovati z imunomodulirajočimi antirevmatiki, ali kadar bolnik teh zdravil ne more jemati.
The fifth study involved patients for whom a biological disease-modifying anti-rheumatic medicine was either not suitable or did not work well enough. 
V peto študijo so bili vključeni bolniki, za katere biološki imunomodulirajoči antirevmatik ni bil primeren ali pa ni bil dovolj učinkovit.
Rinvoq is a medicine for treating adults with rheumatoid arthritis, a disease that causes inflammation of the joints. 
Rinvoq je zdravilo za zdravljenje odraslih z revmatoidnim artritisom, tj. boleznijo, ki povzroča vnetje sklepov.
What are the risks associated with Rinvoq? 
Kakšna tveganja so povezana z zdravilom Rinvoq?
What is Rinvoq and what is it used for? 
Kaj je zdravilo Rinvoq in za kaj se uporablja?
Upadacitinib, the active substance in Rinvoq, is an immunosuppressant. 
Upadacitinib, učinkovina v zdravilu Rinvoq, je imunosupresiv.
The first study was in patients who had not previously been treated with methotrexate. 
Prva študija je vključevala bolnike, ki predhodno niso bili zdravljeni z metotreksatom.
Of the patients who also received Rinvoq, 43% had low disease activity compared with 14% of patients receiving placebo. 
Med bolniki, ki so prejemali tudi zdravilo Rinvoq, jih je 43 % imelo nizko aktivnost bolezni v primerjavi s 14 % bolnikov, ki so prejemali placebo.
Rinvoq was effective at controlling moderate to severe rheumatoid arthritis in patients whose disease had not improved enough with other disease-modifying anti-rheumatic medicines. 
Zdravilo Rinvoq je bilo učinkovito pri nadzoru zmernega do hudega revmatoidnega artritisa pri bolnikih, pri katerih zdravljenje z drugimi imunomodulirajočimi antirevmatiki ni zagotovilo zadostnega izboljšanja.
It found that 45% of the patients treated with Rinvoq on its own had low disease activity after 14 weeks compared with 19% of patients continuing their methotrexate treatment. 
Ugotovljeno je bilo, da je imelo 45 % bolnikov, zdravljenih samo z zdravilom Rinvoq, po 14 tednih nizko aktivnost bolezni v primerjavi z 19 % bolnikov, ki so se še naprej zdravili z metotreksatom.
How is Rinvoq used? 
Kako se zdravilo Rinvoq uporablja?
It found that 45% of patients treated with methotrexate plus Rinvoq had low disease activity after 12 weeks compared with 29% of patients treated with methotrexate plus adalimumab (a biological diseasemodifying anti-rheumatic medicine) and 14% of patients receiving methotrexate plus placebo. 
Ugotovljeno je bilo, da je imelo 45 % bolnikov, zdravljenih z metotreksatom in zdravilom Rinvoq, po 12 tednih nizko aktivnost bolezni v primerjavi z 29 % bolnikov, zdravljenih z metotreksatom in adalimumabom (biološkim imunomodulirajočim antirevmatikom), in 14 % bolnikov, ki so prejemali metotreksat in placebo.
For the full list of side effects of Rinvoq, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Rinvoq, glejte navodilo za uporabo.
Rinvoq can only be obtained with a prescription. 
Predpisovanje in izdaja zdravila Rinvoq je le na recept.
The second study was in patients whose disease was not well controlled with disease-modifying antirheumatic medicines. 
Druga študija je zajela bolnike, pri katerih bolezen ni bila dobro nadzorovana z imunomodulirajočimi antirevmatiki.
The fourth study was also in patients whose disease was not controlled well enough with methotrexate. 
Tudi četrta študija je vključevala bolnike, pri katerih bolezen ni bila dobro nadzorovana z metotreksatom.
How does Rinvoq work? 
Kako zdravilo Rinvoq deluje?
The third study was in patients whose disease was not controlled well with methotrexate. 
Tretja študija je vključevala bolnike, pri katerih bolezen ni bila dobro nadzorovana z metotreksatom.